108 related articles for article (PubMed ID: 33502198)
1. A High-Affinity Peptide Ligand Targeting Syntenin Inhibits Glioblastoma.
Haugaard-Kedström LM; Clemmensen LS; Sereikaite V; Jin Z; Fernandes EFA; Wind B; Abalde-Gil F; Daberger J; Vistrup-Parry M; Aguilar-Morante D; Leblanc R; Egea-Jimenez AL; Albrigtsen M; Jensen KE; Jensen TMT; Ivarsson Y; Vincentelli R; Hamerlik P; Andersen JH; Zimmermann P; Lee W; Strømgaard K
J Med Chem; 2021 Feb; 64(3):1423-1434. PubMed ID: 33502198
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.
Kegelman TP; Wu B; Das SK; Talukdar S; Beckta JM; Hu B; Emdad L; Valerie K; Sarkar D; Furnari FB; Cavenee WK; Wei J; Purves A; De SK; Pellecchia M; Fisher PB
Proc Natl Acad Sci U S A; 2017 Jan; 114(2):370-375. PubMed ID: 28011764
[TBL] [Abstract][Full Text] [Related]
3. Syntenin-targeted peptide blocker inhibits progression of cancer cells.
Liu J; Qu J; Zhou W; Huang Y; Jia L; Huang X; Qian Z; Xia J; Yu Y
Eur J Med Chem; 2018 Jun; 154():354-366. PubMed ID: 29857221
[TBL] [Abstract][Full Text] [Related]
4. Syntenin-syndecan binding requires syndecan-synteny and the co-operation of both PDZ domains of syntenin.
Grootjans JJ; Reekmans G; Ceulemans H; David G
J Biol Chem; 2000 Jun; 275(26):19933-41. PubMed ID: 10770943
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β.
Pradhan AK; Maji S; Bhoopathi P; Talukdar S; Mannangatti P; Guo C; Wang XY; Cartagena LC; Idowu M; Landry JW; Sarkar D; Emdad L; Cavenee WK; Das SK; Fisher PB
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34016751
[TBL] [Abstract][Full Text] [Related]
6. Rethinking Glioblastoma Therapy: MDA-9/Syntenin Targeted Small Molecule.
Das SK; Sarkar D; Cavenee WK; Emdad L; Fisher PB
ACS Chem Neurosci; 2019 Mar; 10(3):1121-1123. PubMed ID: 30681320
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small-Molecule Inhibitor.
Das SK; Kegelman TP; Pradhan AK; Shen XN; Bhoopathi P; Talukdar S; Maji S; Sarkar D; Emdad L; Fisher PB
Mol Cancer Ther; 2019 Nov; 18(11):1997-2007. PubMed ID: 31345950
[TBL] [Abstract][Full Text] [Related]
8. PDZ tandem of human syntenin: crystal structure and functional properties.
Kang BS; Cooper DR; Jelen F; Devedjiev Y; Derewenda U; Dauter Z; Otlewski J; Derewenda ZS
Structure; 2003 Apr; 11(4):459-68. PubMed ID: 12679023
[TBL] [Abstract][Full Text] [Related]
9. Nuclear speckles and nucleoli targeting by PIP2-PDZ domain interactions.
Mortier E; Wuytens G; Leenaerts I; Hannes F; Heung MY; Degeest G; David G; Zimmermann P
EMBO J; 2005 Jul; 24(14):2556-65. PubMed ID: 15961997
[TBL] [Abstract][Full Text] [Related]
10. Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis.
Pradhan AK; Modi J; Maji S; Kumar A; Bhoopathi P; Mannangatti P; Guo C; Afosah DK; Mochel MC; Mukhopadhyay ND; Kirkwood JM; Wang XY; Desai UR; Sarkar D; Emdad L; Das SK; Fisher PB
Mol Cancer Ther; 2023 Oct; 22(10):1115-1127. PubMed ID: 37721536
[TBL] [Abstract][Full Text] [Related]
11. The lymphocyte receptor CD6 interacts with syntenin-1, a scaffolding protein containing PDZ domains.
Gimferrer I; Ibáñez A; Farnós M; Sarrias MR; Fenutría R; Roselló S; Zimmermann P; David G; Vives J; Serra-Pagès C; Lozano F
J Immunol; 2005 Aug; 175(3):1406-14. PubMed ID: 16034076
[TBL] [Abstract][Full Text] [Related]
12. Proteomic peptide phage display uncovers novel interactions of the PDZ1-2 supramodule of syntenin.
Garrido-Urbani S; Garg P; Ghossoub R; Arnold R; Lembo F; Sundell GN; Kim PM; Lopez M; Zimmermann P; Sidhu SS; Ivarsson Y
FEBS Lett; 2016 Jan; 590(1):3-12. PubMed ID: 26787460
[TBL] [Abstract][Full Text] [Related]
13. Peptide-guided nanoparticles for glioblastoma targeting.
Säälik P; Lingasamy P; Toome K; Mastandrea I; Rousso-Noori L; Tobi A; Simón-Gracia L; Hunt H; Paiste P; Kotamraju VR; Bergers G; Asser T; Rätsep T; Ruoslahti E; Bjerkvig R; Friedmann-Morvinski D; Teesalu T
J Control Release; 2019 Aug; 308():109-118. PubMed ID: 31255690
[TBL] [Abstract][Full Text] [Related]
14. Syntenin: PDZ Protein Regulating Signaling Pathways and Cellular Functions.
Shimada T; Yasuda S; Sugiura H; Yamagata K
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31454940
[TBL] [Abstract][Full Text] [Related]
15. Characterization of syntenin, a syndecan-binding PDZ protein, as a component of cell adhesion sites and microfilaments.
Zimmermann P; Tomatis D; Rosas M; Grootjans J; Leenaerts I; Degeest G; Reekmans G; Coomans C; David G
Mol Biol Cell; 2001 Feb; 12(2):339-50. PubMed ID: 11179419
[TBL] [Abstract][Full Text] [Related]
16. New structural insight of C-terminal region of Syntenin-1, enhancing the molecular dimerization and inhibitory function related on Syndecan-4 signaling.
Choi Y; Yun JH; Yoo J; Lee I; Kim H; Son HN; Kim IS; Yoon HS; Zimmermann P; Couchman JR; Cho HS; Oh ES; Lee W
Sci Rep; 2016 Nov; 6():36818. PubMed ID: 27830760
[TBL] [Abstract][Full Text] [Related]
17. Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread.
Garcia M; Hoffer L; Leblanc R; Benmansour F; Feracci M; Derviaux C; Egea-Jimenez AL; Roche P; Zimmermann P; Morelli X; Barral K
Eur J Med Chem; 2021 Nov; 223():113601. PubMed ID: 34153575
[TBL] [Abstract][Full Text] [Related]
18. Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice.
Qin H; Jiang Y; Zhang J; Deng C; Zhong Z
Mol Pharm; 2019 Aug; 16(8):3711-3719. PubMed ID: 31299161
[TBL] [Abstract][Full Text] [Related]
19. Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines.
Kondo E; Tanaka T; Miyake T; Ichikawa T; Hirai M; Adachi M; Yoshikawa K; Ichimura K; Ohara N; Moriwaki A; Date I; Ueda R; Yoshino T
Mol Cancer Ther; 2008 Jun; 7(6):1461-71. PubMed ID: 18566217
[TBL] [Abstract][Full Text] [Related]
20. Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells.
Talukdar S; Das SK; Pradhan AK; Emdad L; Shen XN; Windle JJ; Sarkar D; Fisher PB
Oncotarget; 2016 Aug; 7(34):54102-54119. PubMed ID: 27472461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
